Skip to main content
Verge Genomics

Verge Genomics inks $882 million AI drug discovery pact with AstraZeneca Alexion

By September 15, 2023April 7th, 2024No Comments

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease (“Alexion”) to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.